New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST Nov 8, 2025 11:40AM
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV Oct 3, 2025 09:00AM
RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26 Aug 19, 2025 08:00AM
Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV Jul 25, 2025 09:00AM
Lantern Pharma reports complete response in lymphoma patient trial Jul 23, 2025 07:56AM
View Older Stories

Jul 23, 2025 07:56AM Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
Mar 20, 2024 09:00AM Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
Oct 10, 2023 08:00AM Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
Oct 3, 2023 08:00AM Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma
Sep 25, 2023 08:30AM Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors
Sep 18, 2023 09:00AM Lantern Pharma (LTRN) Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
Sep 18, 2023 09:00AM Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
Aug 31, 2023 08:00AM Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting
Aug 28, 2023 08:00AM Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors
Aug 14, 2023 08:34AM Lantern Pharma (LTRN) Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
Aug 14, 2023 08:30AM Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
Aug 9, 2023 04:01PM Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights
Aug 2, 2023 08:00AM Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET
Jul 17, 2023 08:00AM Lantern Pharma to Participate and Present at Multiple Upcoming Conferences
Jun 26, 2023 08:30AM Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgk
Jun 12, 2023 08:32AM Lantern Pharma (LTRN) Receives FDA Clearance of IND Application for Drug Candidate LP-184
Jun 12, 2023 08:30AM Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
Jun 8, 2023 09:01AM Lantern Pharma (LTRN) Leverages RADR to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
Jun 8, 2023 09:00AM Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
May 17, 2023 08:00AM Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET
May 9, 2023 04:01PM Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights
May 2, 2023 04:01PM Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET
May 2, 2023 07:30AM Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound
Apr 13, 2023 07:31AM Lantern Pharma (LTRN) Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284
Apr 13, 2023 07:30AM Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284
Mar 28, 2023 08:00AM Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer
Mar 21, 2023 04:01PM Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars
Mar 20, 2023 04:01PM Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
Mar 15, 2023 08:00AM Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
Mar 13, 2023 08:00AM Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
Mar 13, 2023 06:02AM Lantern Pharma (LTRN) Has No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank
Mar 13, 2023 06:00AM Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank
Mar 9, 2023 08:01AM Lantern Pharma (LTRN) Announces New Data and Development Focus for LP-100 with PARP Inhibitors
Mar 9, 2023 08:00AM Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors
Mar 8, 2023 08:00AM Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.
Mar 6, 2023 08:00AM Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers
Mar 2, 2023 08:00AM Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials
Feb 27, 2023 08:00AM Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352
Feb 15, 2023 08:00AM Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates
Jan 17, 2023 08:00AM Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023
Jan 5, 2023 08:59AM Lantern Pharma (LTRN) Granted FDA Orphan Drug Designation for LP-284
Jan 5, 2023 08:59AM FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma
Dec 15, 2022 08:00AM Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting
Dec 13, 2022 08:02AM Lantern Pharma (LTRN) Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium
Dec 13, 2022 08:00AM Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)
Dec 2, 2022 08:00AM Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET
Nov 22, 2022 08:00AM Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting
Nov 7, 2022 04:01PM Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights
Nov 2, 2022 08:00AM Lantern Pharma Management to Present at Upcoming Investor Conferences in Q4
Oct 31, 2022 08:00AM Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET
View Older Stories